Skip to content

Study · Animal study (in vivo) · rat · 2005

5 results

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP

Endocrinology7 Apr 2005Cited by 30 (Europe PMC)

PMID15817669 (opens in a new tab)DOI10.1210/en.2004-1286 (opens in a new tab)PepBankPUB-15817669
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male Sprague Dawley rats given subcutaneous doses, CJC‑1295 gave a 4-fold higher GH area under the curve over 2 h than hGRF(1-29).

    In plain wordsIn rats, CJC‑1295 raised growth hormone 4-fold more over 2 hours than the unmodified hGRF(1-29) peptide.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseGH area under the curve over 2 h versus hGRF(1-29)
    Study

    ratn: not reported in source

    male Sprague Dawley rats
    Comparator
    hGRF(1-29)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · scAs given in this study (rat).

    Measurements

    GH AUC fold increase
    4 fold
    CJC-1295 vs hGRF(1-29), 2 h

    Source sentences

    Summary
    The best compound, CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29).
    1 context sentence
    Summary · context
    When the maleimido derivatives were individually administered sc to normal male Sprague Dawley rats, an acute secretion of GH was measured in plasma.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, CJC‑1295 was present in plasma beyond 72 h.

    In plain wordsIn rats, CJC‑1295 stayed in the blood for more than 72 hours.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicablePlasma persistence of CJC-1295
    Study

    ratn: not reported in source

    rats
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Time in plasma
    > 72 h
    CJC-1295

    Source sentences

    Summary
    CJC-1295, a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus, was selected for further pharmacokinetic evaluation, where it was found to be present in plasma beyond 72 h.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In a rat injected with CJC‑1295, Western blot showed a CJC‑1295 immunoreactive species on the serum albumin band from 15 min that remained in circulation beyond 24 h.

    In plain wordsIn a rat, CJC‑1295 attached to albumin in the blood within 15 minutes and stayed for more than 24 hours.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableBinding of CJC-1295 to serum albumin in plasma
    Study

    ratn: not reported in source

    rat injected with CJC-1295
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Time to albumin-bound species
    15 min
    rat plasma
    Time in circulation
    > 24 h
    rat plasma

    Source sentences

    Summary
    A Western blot analysis of the plasma of a rat injected with CJC-1295 showed the presence of a CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 min and remaining in circulation beyond 24 h.
  4. 04LabIn vitro (cells)Activity measurement

    In cultured rat anterior pituitary cells, all three human serum albumin conjugates, which include CJC‑1295, were bioactive in a GH secretion assay.

    In plain wordsIn cultured rat pituitary cells, the three albumin-linked GRF analogs, including CJC‑1295, were active in a growth hormone release test.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseGH secretion in cultured rat anterior pituitary cells
    Study

    ratn: not reported in source

    cultured rat anterior pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells
    1 context sentence
    Summary · context
    Three maleimido derivates of human GH-releasing factor (hGRF)(1-29) were synthesized and bioconjugated to human serum albumin ex vivo.
  5. 05LabIn vitro (cell-free)Activity measurement

    In vitro, all three human serum albumin conjugates of maleimido hGRF(1-29) derivatives, which include CJC‑1295, showed enhanced stability against dipeptidylpeptidase-IV.

    In plain wordsIn lab tests, the three albumin-linked GRF analogs, including CJC‑1295, resisted breakdown by dipeptidylpeptidase-IV better.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseStability against dipeptidylpeptidase-IV
    Study

    n: not reported in source

    hGRF(1-29) albumin conjugates in vitro
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    All three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV
    1 context sentence
    Summary · context
    Three maleimido derivates of human GH-releasing factor (hGRF)(1-29) were synthesized and bioconjugated to human serum albumin ex vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.